Eton Pharmaceuticals, Inc. (ETON)
| Previous Close | 3.2500 |
| Open | 3.2700 |
| Bid | 3.2300 x 100 |
| Ask | 3.3600 x 100 |
| Day's Range | 3.2500 - 3.4625 |
| 52 Week Range | 2.4200 - 5.8100 |
| Volume | |
| Avg. Volume | 62,698 |
| Market Cap | 84.257M |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | Mar 11, 2024 - Mar 26, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireEton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call pointTransaction is expected to be accretive to 2024 earningsEstimated peak sales of more than $10 million annuallyU.S. phenylketonuria ("PKU") medical formula market estimated to be $100 million annually DEER PARK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company foc
Insider MonkeyEton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2023 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2023 Earnings Call Transcript March 14, 2024 Eton Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Eton Pharmaceuticals’ Fourth Quarter 2023 Financial Results Conference Call. At this time, […]
- Thomson Reuters StreetEvents
Q4 2023 Eton Pharmaceuticals Inc Earnings Call
Q4 2023 Eton Pharmaceuticals Inc Earnings Call
